Yuyu Pharma Eyes Animal Health Market to Broaden Drug Development Opportunities
Key Points
- Yuyu Pharma is exploring veterinary medicine as a second market for its drug development technologies under a "One Pipeline, Two Markets" strategy.
- CEO Robert Wonsang Yu outlined the approach at BIOPLUS-INTERPHEX KOREA 2026, citing the One Health connection between human and animal health.
- The move would extend the South Korean company's 85-year healthcare history into companion animal drug development.
Yuyu Pharma is exploring opportunities in veterinary medicine as a way to expand its pharmaceutical business and identify new avenues for drug development in human healthcare. The South Korean pharmaceutical company outlined its strategy at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), where CEO Robert Wonsang Yu participated in a panel discussion on dual commercialization strategies for human and animal medicines. The discussion examined how pharmaceutical companies can apply existing technologies and research capabilities across both markets.
Founded in 1941, Yuyu Pharma has built its business around pharmaceuticals and healthcare. The company is now evaluating opportunities in biotechnology, animal health, and emerging drug development technologies as it looks to diversify its growth strategy. The approach, described as “One Pipeline, Two Markets,” centers on the potential for scientific discoveries and technologies developed for human medicine to be applied to veterinary treatments. Research in animal health could also generate insights that inform future human drug discovery, although the extent of these potential applications will depend on the specific technologies and research involved.
Yu said developing medicines for companion animals could help the company build additional drug development expertise and capabilities. He also highlighted the One Health concept, which recognizes the interconnections between human, animal, and environmental health. The company sees opportunities to apply its pharmaceutical experience to the companion animal healthcare market while developing new partnerships and expanding its research capabilities. Advances in biotechnology, drug delivery, and pharmaceutical research are creating potential opportunities for companies with established drug development expertise to enter veterinary medicine.
For Yuyu Pharma, the strategy represents a potential extension of its 85-year history in healthcare. By exploring veterinary drug development alongside its human pharmaceutical business, the company aims to identify new markets and technologies that could support future innovation across both areas.
For more information, visit https://yuyu.co.kr.
Total Page Views: 5
